Philadelphia too, proves to be unlucky for Xarelto Plaintiff

Philadelphia too, proves to be unlucky for Xarelto Plaintiff

Introduction

Just when Xarelto plaintiff attorneys were rejoicing and preparing on the lines of the first Philadelphia Xarelto trial which brought in the first-ever win for the plaintiffs, the verdict was reversed. The $28 million jury verdict was awarded to a plaintiff who suffered gastrointestinal bleeding allegedly caused by the defendants', Bayer AG and Johnson & Johnson, subsidiary Janssen Pharmaceuticals' blood thinner Xarelto. The allegation which won the verdict was based on the grounds of failing to adequately warn about the risks of the blood-thinner Xarelto.

However, Common Pleas Judge Michael Erdos reversed the decision based on a very narrow issue related to the plaintiff’s prescribing physician. The plaintiff's attorney has informed that the decision would be appealed, on the other hand, the defendant’s spokesperson states that the companies have always warned of bleeding events and will continue to defend against allegations made in this litigation.

Xarelto lawsuits are centralized in the U.S. District Court for the Eastern District of Louisiana before Judge Eldon E. Fallon as a part of MDL- 2592 Xarelto Products Liability Litigation. Currently, more than 22,000 Xarelto cases are pending in several courts across the country.